|Business Reports - Market Report|
Monoclonal antibodies: 2009 update
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy area, geography, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
The global prescription pharmaceutical market is expected to face a decline in sales over 2012 to 2013 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.
Over the forecast period monoclonal antibodies are predicted to enjoy double-digit growth while small molecule drugs face declining growth rates. The main barrier to sales growth for small molecules, and particularly in the US, is exposure to material generic competition, which Datamonitor believes will have no effect on mAbs out to 2014.
This attractive growth rate and sales return potential has made mAb companies a prime acquisition target in recent years, even during a period of economic uncertainty, with a number of key acquisitions made during 2008-09.
Read also at Pharmaceutical Licensing Network
Newer news items
|< Prev||Next >|
Finding and adding contacts
The search function “Peple Finder” enables you to serch the list of registered users and to find contacts that are relevant to you. This powersearch will look into diffrent fieals of member profile. For instance, you can serarch for specific name, company, city, country or interest related to other members.
You can connect to other users. On the profile page click on tab Connections>Request Connection . You should keep quality in mind choosing contacts you want to add.